Clinical Trial

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Study acronym: EOS-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Protocol Amendment History 2 changes
minor Completion pushed: 2027-03 -> 2028-03 2026-07-11
minor Trial arms changed: 2 -> 3 2026-04-28
Trial Details
NCT Number NCT06596252
Lead Sponsor Dr. Falk Pharma GmbH
Conditions Eosinophilic Esophagitis
Enrollment 308 participants
Start Date 2021-05-21
Primary Completion 2026-12 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-10